CHARACTRISTICS OF CYTOKINES, PHENOTIPIC FEATURES AND NEUTROPHILSPHAGOCYTOSIS ACTIVITY IN ASTHMATIC PATIENTS DURING EXACERBATION

T V Borisova; S I Sokurenko; A V Karaulov

doi:10.17816/clinpract4311-19

Journal of Clinical Practice ›› 2013, Vol. 4 ›› Issue (3) : 11 -19. DOI: 10.17816/clinpract4311-19

Articles

research-article

CHARACTRISTICS OF CYTOKINES, PHENOTIPIC FEATURES AND NEUTROPHILSPHAGOCYTOSIS ACTIVITY IN ASTHMATIC PATIENTS DURING EXACERBATION

Author information +

History +

PDF

Abstract

The aim of our study was to measure the level of IL -8, IL-6, IL-4, IL-17 depending on spontaneous or induced release by peripheral blood leukocytes in patients with bronchial asthma exacerbation with comparative analysis of asthmatics' blood neutrophils phenotypic features. The obtained data indicate that the level either pro-inflammatory or anti-inflammatory cytokines was increased in patients with asthma exacerbations and significant increase of concentration of CD45+CD66b+CD11b+ cells in comparing with healthy donors. We determined that during asthma exacerbation the concentration of CD45+, CD66b+, CD11b+ blood granulocytes almost doubled in comparing with healthy donors. Also there is a significant increasing of blood granulocytes' phagocytosis activity. We observed the elevated level of spontaneous production of inflammatory mediators. Moreover, the stimulation of cytokines synthesis and release in patients with asthma does not always lead to increase of induced level of cytokines in contrast to healthy donors.

Keywords

bronchial asthma / cytokines / neutrophiles / phagocytosis

Cite this article

Download citation ▾

T V Borisova, S I Sokurenko, A V Karaulov. CHARACTRISTICS OF CYTOKINES, PHENOTIPIC FEATURES AND NEUTROPHILSPHAGOCYTOSIS ACTIVITY IN ASTHMATIC PATIENTS DURING EXACERBATION. Journal of Clinical Practice, 2013, 4(3): 11-19 DOI:10.17816/clinpract4311-19

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Kips J.C., O'Connor B.J., Langley S.J., Woodcock A., Kerstjens H.A.M., Postma D.S., Danzig M., Cuss F., Pauwels R.A. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655-9.

[2]	Lloyd C. M. Hawrylowicz C. M. Regulatory T cells in asthma. Immunity. 2009 Sep 18;31(3):438-49

[3]	Desai D., Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clinical and Experimental Immunology, 2009.158: 10-19.

[4]	Boyton R.J., Altamann D.M. Asthma: New developments in cytokine regulation. Clin. Exp. Immunol. 2004;136:13-4.

[5]	Сильвестров В.П., Караулов А.В. Иммунологическая недостаточность при заболеваниях органов дыхания (вопросы диагностики, патогенеза и лечения). Тер.арх., 1985, т. 57, №3, с. 3-9.

[6]	Караулов А.В., Анисимова Н.Ю., Должикова Ю.И. и др. Спонтанная и индуцированная продукция цитокинов лейкоцитами периферической крови у больных бронхиальной астмой в стадии обострения// Российский биотерапевтический журнал. 2010. Т.9, №.4 С. 93-96.

[7]	Bhupinder S Mann and Kian F Chung. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy//Respiratory Research 2006, 7:59.

[8]	Chung K.F., Barnes P.J. Cytokines in asthma. Thorax. 1999;54:825-857.

[9]	Gibson PG, Simpson JL, Saltos N: Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001, 119:1329-1336.